This patent concerns placenta-derived multi-potent stem cells and the cellular therapeutic agent containing thereof. To be more specific, amniotic, serous and basal decidua- or placenta-derived tissues are cultured in a culture medium containing bFGF, and they have the following characteristics after the culture process:
(a) Shows positive immunological responses to CD29, CD44, CD73, CD90 and CD105 and negative immunological responses to CD31, CD34, CD45 and HLA-DR;
(b) Positive immunological responses are shown in relation to OCT4 and SSEA4;
(c) The stem cells grow after adhering to plastic and are characterized by round and spindle shapes in terms of morphology. Spheres are formed using FM sphere-forming medium so that the stem cells can be maintained in their undifferentiated state.
(d) This patent concerns the method of manufacturing placenta-derived stem cells with an ability to differentiate into cells derived from the mesodermal, endodermal and ectodermal cells as well as the placenta-derived stem cells that are acquired.
The multi-potent stem cells concerned have the ability to differentiate into myocytes, vascular endothelial cells, osteoblasts, neurocytes, astrocytes, adipocytes, chondroblasts or insulin-secreting pancreatic beta cells, and thus can be used to effectively treat osteoporosis, osteoarthritis, neural diseases and diabetes and to form breast tissue.